As the field of epilepsy management continues to evolve, healthcare professionals must stay abreast of the latest developments to provide optimal care for patients. This article provides a comprehensive update on recent advances in epilepsy management.
Several new AEDs have gained approval for use in recent years. These include cenobamate, which demonstrates significant efficacy in focal-onset seizures, and fenfluramine, approved for Dravet syndrome. These drugs offer new options for patients with refractory epilepsy.
Neuromodulation therapies such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS) have shown promising results in reducing seizure frequency and severity. RNS, in particular, has been recognized for its ability to predict and abort seizures before they occur.
Genetic testing has become increasingly important in epilepsy management. Identification of specific genetic mutations can guide treatment decisions and provide prognostic information. Additionally, it enables personalized medicine, tailoring treatment to the individual's genetic profile.
Surgical interventions remain a valuable option for patients with drug-resistant epilepsy. Advances in imaging and surgical techniques have improved the success rates of these procedures. Minimally invasive techniques, such as laser interstitial thermal therapy, have shown promise in reducing morbidity and improving recovery times.
In conclusion, the field of epilepsy management is rapidly evolving with the introduction of new AEDs, neuromodulation therapies, advancements in genetic testing, and surgical innovations. Healthcare professionals must remain updated on these developments to provide the best possible care for patients with epilepsy.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation